The Complex Role of the Lung in the Pathogenesis and Clinical Outcomes of Rheumatoid Arthritis

1.

Demoruelle MK, Parish MC, Derber LA, Kolfenbach JR, Hughes-Austin JM, Weisman MH, et al. Performance of anti-cyclic citrullinated peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease. Arthritis Rheum. 2013;65(9):2243–52. doi:10.1002/art.38017.CrossRefPubMedPubMedCentral

2.

Spector TD. Rheumatoid arthritis. Rheum Dis Clin N Am. 1990;16(3):513–37.

3.

Turesson C, Jacobsson LT, Sturfelt G, Matteson EL, Mathsson L, Ronnelid J. Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(1):59–64. doi:10.1136/ard.2006.054445.CrossRefPubMed

4.

Nannini C, Ryu JH, Matteson EL. Lung disease in rheumatoid arthritis. Curr Opin Rheumatol. 2008;20(3):340–6. doi:10.1097/BOR.0b013e3282f798ed.CrossRefPubMed

5.

Ascherman DP. Interstitial lung disease in rheumatoid arthritis. Curr Rheumatol Rep. 2010;12(5):363–9. doi:10.1007/s11926-010-0116-z.CrossRefPubMed

6.

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.CrossRefPubMed

7.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham 3rd CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. doi:10.1002/art.27584.CrossRefPubMed

8.

Gerlag DM, Raza K, van Baarsen LG, Brouwer E, Buckley CD, Burmester GR, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis. 2012;71(5):638–41. doi:10.1136/annrheumdis-2011-200990.CrossRefPubMedPubMedCentral

9.

Chatzidionisyou A, Catrina AI. The lung in rheumatoid arthritis, cause or consequence? Curr Opin Rheumatol. 2016;28(1):76–82. doi:10.1097/BOR.0000000000000238.CrossRefPubMed

10.

Gabbay E, Tarala R, Will R, Carroll G, Adler B, Cameron D, et al. Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med. 1997;156(2 Pt 1):528–35. doi:10.1164/ajrccm.156.2.9609016.CrossRefPubMed

11.

van den Oever IA, Sattar N, Nurmohamed MT. Thromboembolic and cardiovascular risk in rheumatoid arthritis: role of the haemostatic system. Ann Rheum Dis. 2014;73(6):954–7. doi:10.1136/annrheumdis-2013-204767.CrossRefPubMed

12.

Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis. 2015;7(6):247–67. doi:10.1177/1759720x15612250.CrossRefPubMedPubMedCentral

13.

Tsuchiya Y, Takayanagi N, Sugiura H, Miyahara Y, Tokunaga D, Kawabata Y, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J. 2011;37(6):1411–7. doi:10.1183/09031936.00019210.CrossRefPubMed

14.•

Sparks JA, Chang SC, Liao KP, Lu B, Fine AR, Solomon DH, et al. Rheumatoid arthritis and mortality among women during 36 years of prospective follow-up: results from the Nurses’ Health Study. Arthritis Care Res (Hoboken). 2016;68(6):753–62. doi:10.1002/acr.22752. Identifies that lung disease is a leading cause of mortality in RA. Furthermore, identifies that obstructive lung disease rather than ILD may be important in mortality.CrossRef

15.•

Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, et al. Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2013;65(8):1243–50. doi:10.1002/acr.21986. Describes the prevalence and incidence of lung disease in RA.CrossRef

16.

Sparks JA, Chang SC, Karlson EW. Reply. Arthritis Care Res (Hoboken). 2016;68(8):1211–2. doi:10.1002/acr.22838.CrossRef

17.

Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics—a large multicentre UK study. Rheumatology (Oxford). 2014;53(9):1676–82. doi:10.1093/rheumatology/keu165.CrossRef

18.•

Rocha-Munoz AD, Ponce-Guarneros M, Gamez-Nava JI, Olivas-Flores EM, Mejia M, Juarez-Contreras P, et al. Anti-cyclic citrullinated peptide antibodies and severity of interstitial lung disease in women with rheumatoid arthritis. J Immunol Res. 2015;2015:151626. doi:10.1155/2015/151626. Review of the risk factors for RA-related ILD, including elevated ACPA.PubMedPubMedCentral

19.•

Restrepo JF, del Rincon I, Battafarano DF, Haas RW, Doria M, Escalante A. Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis. Clin Rheumatol. 2015;34(9):1529–36. doi:10.1007/s10067-015-3025-8.CrossRefPubMed

20.•

Giles JT, Danoff SK, Sokolove J, Wagner CA, Winchester R, Pappas DA, et al. Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Ann Rheum Dis. 2014;73(8):1487–94. doi:10.1136/annrheumdis-2012-203160. Primary study identifying that expanded ACPA repertoire is related to ILD.CrossRefPubMed

21.

Vencovsky J, Machacek S, Sedova L, Kafkova J, Gatterova J, Pesakova V, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis. 2003;62(5):427–30.CrossRefPubMedPubMedCentral

22.•

Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012;106(11):1591–9. doi:10.1016/j.rmed.2012.07.006. Primary study evaluating different types of lung disease in RA (airways and ILD) and separate risk factors for each of these manifestations.CrossRefPubMed

23.•

Inui N, Enomoto N, Suda T, Kageyama Y, Watanabe H, Chida K. Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis. Clin Biochem. 2008;41(13):1074–7. doi:10.1016/j.clinbiochem.2008.06.014. Primary studying identifying that RA-related autoantibodies can be generated in the lung in individuals without classifiable RA.CrossRefPubMed

24.

Perry E, Kelly C, Eggleton P, De Soyza A, Hutchinson D. The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? Rheumatology (Oxford). 2014;53(11):1940–50. doi:10.1093/rheumatology/keu195.CrossRef

25.

Perry E, Eggleton P, De Soyza A, Hutchinson D, Kelly C. Increased disease activity, severity and autoantibody positivity in rheumatoid arthritis patients with co-existent bronchiectasis. International Journal of Rheumatic Diseases. 2015. doi:10.1111/1756-185x.12702

26.

Walker WC. Pulmonary infections and rheumatoid arthritis. Q J Med. 1967;36(142):239–51.PubMed

27.

Kaushik VV, Hutchinson D, Desmond J, Lynch MP, Dawson JK. Association between bronchiectasis and smoking in patients with rheumatoid arthritis. Ann Rheum Dis. 2004;63(8):1001–2. doi:10.1136/ard.2003.015123.CrossRefPubMedPubMedCentral

28.

Perry E, Stenton C, Kelly C, Eggleton P, Hutchinson D, De Soyza A. RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients. Eur Respir J. 2014;44(4):1082–5. doi:10.1183/09031936.00064014.CrossRefPubMed

29.

Janssen KM, de Smit MJ, Brouwer E, de Kok FA, Kraan J, Altenburg J, et al. Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study. Arthritis Res Ther. 2015;17:174. doi:10.1186/s13075-015-0690-6.CrossRefPubMedPubMedCentral

30.

Demoruelle MK, Weisman MH, Simonian PL, Lynch DA, Sachs PB, Pedraza IF, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64(6):1756–61. doi:10.1002/art.34344.CrossRefPubMed

31.

Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004;33(2):65–72.CrossRefPubMed

32.

Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax. 2001;56(8):622–7.CrossRefPubMedPubMedCentral

33.

Skare TL, Nakano I, Escuissiato DL, Batistetti R, Rodrigues Tde O, Silva MB. Pulmonary changes on high-resolution computed tomography of patients with rheumatoid arthritis and their association with clinical, demographic, serological and therapeutic variables. Rev Bras Reumatol. 2011;51(4):325–30. 36-7.PubMed

34.

Zhu J, Zhou Y, Chen X, Li J. A metaanalysis of the increased risk of rheumatoid arthritis-related pulmonary disease as a result of serum anticitrullinated protein antibody positivity. J Rheumatol. 2014;41(7):1282–9. doi:10.3899/jrheum.131341.CrossRefPubMed

35.

Sokolove J, Bromberg R, Deane KD, Lahey LJ, Derber LA, Chandra PE, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7(5):e35296. doi:10.1371/journal.pone.0035296.CrossRefPubMedPubMedCentral

36.

Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54(1):38–46. doi:10.1002/art.21575.CrossRefPubMed

37.

Kallberg H, Ding B, Padyukov L, Bengtsson C, Ronnelid J, Klareskog L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis. 2011;70(3):508–11. doi:10.1136/ard.2009.120899.CrossRefPubMed

38.

Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008;67(10):1488–92. doi:10.1136/ard.2007.075192.CrossRefPubMed

39.

Giles JT, Darrah E, Danoff S, Johnson C, Andrade F, Rosen A, et al. Association of cross-reactive antibodies targeting peptidyl-arginine deiminase 3 and 4 with rheumatoid arthritis-associated interstitial lung disease. PLoS One. 2014;9(6):e98794. doi:10.1371/journal.pone.0098794.CrossRefPubMedPubMedCentral

40.

Darrah E, Giles JT, Ols ML, Bull HG, Andrade F, Rosen A. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med. 2013;5(186):186ra65. doi:10.1126/scitranslmed.3005370.CrossRefPubMedPubMedCentral

41.

Shelef MA, Bennin DA, Mosher DF, Huttenlocher A. Citrullination of fibronectin modulates synovial fibroblast behavior. Arthritis Res Ther. 2012;14(6):R240. doi:10.1186/ar4083.CrossRefPubMedPubMedCentral

42.

Reynisdottir G, Karimi R, Joshua V, Olsen H, Hensvold AH, Harju A, et al. Structural changes and antibody enrichment in the lungs are early features of anti-citrullinated protein antibody-positive rheumatoid arthritis. Arthritis Rheumatol. 2014;66(1):31–9. doi:10.1002/art.38201.CrossRefPubMed

43.

Catrina AI, Ytterberg AJ, Reynisdottir G, Malmstrom V, Klareskog L. Lungs, joints and immunity against citrullinated proteins in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(11):645–53. doi:10.1038/nrrheum.2014.115.CrossRefPubMed

44.

Sparks JA, Karlson EW. The roles of cigarette smoking and the lung in the transitions between phases of preclinical rheumatoid arthritis. Curr Rheumatol Rep. 2016;18(3):15. doi:10.1007/s11926-016-0563-2.CrossRefPubMed

45.

Larsen JM, Steen-Jensen DB, Laursen JM, Sondergaard JN, Musavian HS, Butt TM, et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS One. 2012;7(2):e31976. doi:10.1371/journal.pone.0031976.CrossRefPubMedPubMedCentral

46.

Thannickal VJ, Toews GB, White ES, Lynch 3rd JP, Martinez FJ. Mechanisms of pulmonary fibrosis. Annu Rev Med. 2004;55:395–417. doi:10.1146/annurev.med.55.091902.103810.CrossRefPubMed

47.

Turesson C, Matteson EL, Colby TV, Vuk-Pavlovic Z, Vassallo R, Weyand CM, et al. Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis. Arthritis Rheum. 2005;52(1):73–9. doi:10.1002/art.20765.CrossRefPubMed

48.

Atkins SR, Turesson C, Myers JL, Tazelaar HD, Ryu JH, Matteson EL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia. Arthritis Rheum. 2006;54(2):635–41. doi:10.1002/art.21758.CrossRefPubMed

49.

Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, Randall TD. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest. 2006;116(12):3183–94. doi:10.1172/JCI28756.CrossRefPubMedPubMedCentral

50.

Reynisdottir G, Olsen H, Joshua V, Engstrom M, Forsslund H, Karimi R et al. Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis. Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-2015-208216

51.

Brown LE DM, Parish MC, Feser ML, Sachs PB, Heinz DE, Cool CD, Deane KD. Ectopic lymphoid tissue in the lung is associated with serum rheumatoid arthritis-related autoantibodies even in absence of clinically apparent rheumatoid arthritis [Abstract 963]. Arthritis Rheumatol. 2015;67 (S10): abstract 963. doi: 10.1002/art.39448.

52.

Harlow L, Rosas IO, Gochuico BR, Mikuls TR, Dellaripa PF, Oddis CV, et al. Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheum. 2013;65(4):869–79. doi:10.1002/art.37881.CrossRefPubMed

53.

Willis VC, Demoruelle MK, Derber LA, Chartier-Logan CJ, Parish MC, Pedraza IF, et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum. 2013;65(10):2545–54. doi:10.1002/art.38066.PubMedPubMedCentral

54.

Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50(2):380–6. doi:10.1002/art.20018.CrossRefPubMed

55.

Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Hamann D, van Schaardenburg D, et al. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann Rheum Dis. 2014;73(4):780–3. doi:10.1136/annrheumdis-2013-204154.CrossRefPubMed

56.

Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol. 2014;26(1):101–7. doi:10.1097/bor.0000000000000008.CrossRefPubMedPubMedCentral

57.

Kolfenbach JR, Deane KD, Derber LA, O’Donnell CI, Gilliland WR, Edison JD, et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2633–9. doi:10.1002/art.27570.CrossRefPubMedPubMedCentral

58.

Barra L, Scinocca M, Saunders S, Bhayana R, Rohekar S, Racape M, et al. Anti-citrullinated protein antibodies in unaffected first-degree relatives of rheumatoid arthritis patients. Arthritis Rheum. 2013;65(6):1439–47. doi:10.1002/art.37911.CrossRefPubMed

59.

Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol. 2014;26(1):64–71. doi:10.1097/BOR.0000000000000017.CrossRefPubMedPubMedCentral

60.

Gizinski AM, Mascolo M, Loucks JL, Kervitsky A, Meehan RT, Brown KK, et al. Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA. Clin Rheumatol. 2009;28(5):611–3. doi:10.1007/s10067-009-1128-9.CrossRefPubMedPubMedCentral

61.

Mikuls TR, Payne JB, Deane KD, Thiele GM. Autoimmunity of the lung and oral mucosa in a multisystem inflammatory disease: the spark that lights the fire in rheumatoid arthritis? J Allergy Clin Immunol. 2016;137(1):28–34. doi:10.1016/j.jaci.2015.10.024.CrossRefPubMed

62.

Wilsher M, Voight L, Milne D, Teh M, Good N, Kolbe J, et al. Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis. Respir Med. 2012;106(10):1441–6. doi:10.1016/j.rmed.2012.06.020.CrossRefPubMed

63.

Fischer A, Solomon JJ, du Bois RM, Deane KD, Olson AL, Fernandez-Perez ER, et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir Med. 2012;106(7):1040–7. doi:10.1016/j.rmed.2012.03.006.CrossRefPubMedPubMedCentral

64.

Svard A, Kastbom A, Reckner-Olsson A, Skogh T. Presence and utility of IgA-class antibodies to cyclic citrullinated peptides in early rheumatoid arthritis: the Swedish TIRA project. Arthritis Res Ther. 2008;10(4):R75. doi:10.1186/ar2449.CrossRefPubMedPubMedCentral

65.

Ytterberg AJ, Joshua V, Reynisdottir G, Tarasova NK, Rutishauser D, Ossipova E, et al. Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis. 2015;74(9):1772–7. doi:10.1136/annrheumdis-2013-204912.CrossRefPubMed

66.

Ossipova E, Cerqueira CF, Reed E, Kharlamova N, Israelsson L, Holmdahl R, et al. Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint. Arthritis Res Ther. 2014;16(4):R167. doi:10.1186/ar4683.CrossRefPubMedPubMedCentral

67.

Liu X, Zou Q, Zeng B, Fang Y, Wei H. Analysis of fecal Lactobacillus community structure in patients with early rheumatoid arthritis. Curr Microbiol. 2013;67(2):170–6. doi:10.1007/s00284-013-0338-1.CrossRefPubMed

68.

Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976–87. doi:10.1183/13993003.00150-2015.CrossRefPubMed

69.

Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016. doi:10.1183/13993003.01565-2015

70.

Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2005;17(6):701–6.CrossRefPubMed

71.

Levine SM, Raben N, Xie D, Askin FB, Tuder R, Mullins M, et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum. 2007;56(8):2729–39. doi:10.1002/art.22790.CrossRefPubMed

72.

Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C. Anti-Ro52 antibodies and interstitial lung disease in connective tissue diseases excluding scleroderma. ISRN Rheumatol. 2012;2012:415272. doi:10.5402/2012/415272.CrossRefPubMedPubMedCentral

73.

Yazisiz V, Arslan G, Ozbudak IH, Turker S, Erbasan F, Avci AB, et al. Lung involvement in patients with primary Sjogren’s syndrome: what are the predictors? Rheumatol Int. 2010;30(10):1317–24. doi:10.1007/s00296-009-1152-8.CrossRefPubMed

74.

Quirke AM, Perry E, Cartwright A, Kelly C, De Soyza A, Eggleton P, et al. Bronchiectasis is a model for chronic bacterial infection inducing autoimmunity in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(9):2335–42. doi:10.1002/art.39226.CrossRefPubMedPubMedCentral

75.

Yang IV, Fingerlin TE, Evans CM, Schwarz MI, Schwartz DA. MUC5B and idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2015;12 Suppl 2:S193–9. doi:10.1513/AnnalsATS.201503-110AW.PubMedPubMedCentral

76.

Adegunsoye A, Strek ME. Therapeutic approach to adult fibrotic lung diseases. Chest. 2016. doi:10.1016/j.chest.2016.07.027

Medicine Matters Rheumatology

Abstract